Theoretical Insights into Imidazolidine Oxidation of Imidacloprid by Cytochrome P450 3A4. 2018

Mei Lin Zheng, and Chao Rui Li, and Qun Hua Bai, and Hong Xiao, and Wei Hu, and Ying Xue, and Jie Ying Gao
School of Public Health and Management, Chongqing Medical University, Chongqing 400016, PR China.

The metabolic mechanisms for imidazolidine oxidation of imidacloprid (IMI) by cytochrome P450 3A4 (CYP3A4) have been investigated using quantum mechanical/molecular mechanical (QM/MM) calculations. The binding mode of CYP3A4 with IMI is examined by molecular docking in collaboration with molecular dynamics (MD) simulations. The results show that there are six amino acid residues, involving Arg192, Phe195, Ile349, Ala285, Phe284 and Phe88, closely distributed around the IMI. The binding free energy analysis exhibits that the CYP3A4-IMI binding structure is stabilized by electrostatic interaction and van der Waals interaction. Arg192 plays a major role in the binding of CYP3A4 with IMI based on its polarity and the hydrogen bond between the H atom in Arg192 side chain and the nitryl O atom of IMI. Two possible pathways, pathway 1 and pathway 2, are evaluated. Two spin states of the Fe (III) center, quartet and doublet, are considered. The free energy calculations are done using QM/MM steered molecular dynamics (SMD) simulation at the B3LYP/6-31 + G(d):ff14SB level for two pathways. The ONIOM QM/MM single-point calculations at the B3LYP/6-311 + G(2d,2p):ff99SB//B3LYP/6-31 + G(d): ff14SB and M06-2X/6-311 + G(2d,2p):ff99SB//B3LYP/6-31 + G(d):ff14SB levels are carried out to obtain more credible energy information. The results indicate that for both pathways, the free energy barriers on the low-spin doublet state are lower than those on the high-spin quartet state. Both pathways are the stepwise processes. Pathway 1 has higher possibility to occur with the free energy barriers being lower by 10-15 kcal·mol-1 compared with pathway 2, which gives rise to trans-5'-hydroxyl-IMI as the final product. The first proton-transfer is the rate-limiting step and the calculated activation free energy is consistent with the experimental conclusion.

UI MeSH Term Description Entries
D009574 Nitro Compounds Compounds having the nitro group, -NO2, attached to carbon. When attached to nitrogen they are nitramines and attached to oxygen they are NITRATES. Nitrated Compounds
D010084 Oxidation-Reduction A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471). Redox,Oxidation Reduction
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D006860 Hydrogen Bonding A low-energy attractive force between hydrogen and another element. It plays a major role in determining the properties of water, proteins, and other compounds. Hydrogen Bonds,Bond, Hydrogen,Hydrogen Bond
D000073943 Neonicotinoids A class of insecticides that are structurally similar to NICOTINE and have physiologically similar effects as agonists of NICOTINIC ACETYLCHOLINE RECEPTORS, but are less toxic to vertebrates. They are widely used in agriculture. Neonicotinoid
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D048289 Imidazolidines Compounds based on reduced IMIDAZOLINES which contain no double bonds in the ring. Imidazolidine
D051544 Cytochrome P-450 CYP3A A cytochrome P-450 suptype that has specificity for a broad variety of lipophilic compounds, including STEROIDS; FATTY ACIDS; and XENOBIOTICS. This enzyme has clinical significance due to its ability to metabolize a diverse array of clinically important drugs such as CYCLOSPORINE; VERAPAMIL; and MIDAZOLAM. This enzyme also catalyzes the N-demethylation of ERYTHROMYCIN. CYP3A,CYP3A4,CYP3A5,Cytochrome P-450 CYP3A4,Cytochrome P-450 CYP3A5,Cytochrome P-450IIIA,Cytochrome P450 3A,Cytochrome P450 3A4,Cytochrome P450 3A5,Erythromycin N-Demethylase,Taurochenodeoxycholate 6-alpha-Monooxygenase,3A5, Cytochrome P450,6-alpha-Monooxygenase, Taurochenodeoxycholate,Cytochrome P 450 CYP3A,Cytochrome P 450 CYP3A4,Cytochrome P 450 CYP3A5,Cytochrome P 450IIIA,Erythromycin N Demethylase,N-Demethylase, Erythromycin,P-450 CYP3A, Cytochrome,P-450 CYP3A4, Cytochrome,P-450 CYP3A5, Cytochrome,P-450IIIA, Cytochrome,P450 3A, Cytochrome,P450 3A5, Cytochrome,Taurochenodeoxycholate 6 alpha Monooxygenase
D056004 Molecular Dynamics Simulation A computer simulation developed to study the motion of molecules over a period of time. Molecular Dynamics Simulations,Molecular Dynamics,Dynamic, Molecular,Dynamics Simulation, Molecular,Dynamics Simulations, Molecular,Dynamics, Molecular,Molecular Dynamic,Simulation, Molecular Dynamics,Simulations, Molecular Dynamics

Related Publications

Mei Lin Zheng, and Chao Rui Li, and Qun Hua Bai, and Hong Xiao, and Wei Hu, and Ying Xue, and Jie Ying Gao
June 2002, Toxicology letters,
Mei Lin Zheng, and Chao Rui Li, and Qun Hua Bai, and Hong Xiao, and Wei Hu, and Ying Xue, and Jie Ying Gao
January 2009, Nature protocols,
Mei Lin Zheng, and Chao Rui Li, and Qun Hua Bai, and Hong Xiao, and Wei Hu, and Ying Xue, and Jie Ying Gao
January 2017, Proceedings of the National Academy of Sciences of the United States of America,
Mei Lin Zheng, and Chao Rui Li, and Qun Hua Bai, and Hong Xiao, and Wei Hu, and Ying Xue, and Jie Ying Gao
May 1998, European journal of clinical pharmacology,
Mei Lin Zheng, and Chao Rui Li, and Qun Hua Bai, and Hong Xiao, and Wei Hu, and Ying Xue, and Jie Ying Gao
January 2006, Acta poloniae pharmaceutica,
Mei Lin Zheng, and Chao Rui Li, and Qun Hua Bai, and Hong Xiao, and Wei Hu, and Ying Xue, and Jie Ying Gao
November 2022, Journal of chemical information and modeling,
Mei Lin Zheng, and Chao Rui Li, and Qun Hua Bai, and Hong Xiao, and Wei Hu, and Ying Xue, and Jie Ying Gao
September 2021, Chemosphere,
Mei Lin Zheng, and Chao Rui Li, and Qun Hua Bai, and Hong Xiao, and Wei Hu, and Ying Xue, and Jie Ying Gao
January 2005, Trends in biochemical sciences,
Mei Lin Zheng, and Chao Rui Li, and Qun Hua Bai, and Hong Xiao, and Wei Hu, and Ying Xue, and Jie Ying Gao
January 2003, Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica,
Mei Lin Zheng, and Chao Rui Li, and Qun Hua Bai, and Hong Xiao, and Wei Hu, and Ying Xue, and Jie Ying Gao
May 2011, The Journal of biological chemistry,
Copied contents to your clipboard!